Covid-19 roundup: Trump pushes his new favorite, untested drug; CRISPR outlines crippling impact of Covid-19
President Trump has a new favorite Covid-19 drug.
After a conversation with Japanese Prime Minister Shinzo Abe, Politico reports, the president is pressuring the FDA to issue emergency use authorization for favipiravir, a flu drug that showed glimpses of success in China but remains unproven and carries a list of worrying side effects. The push comes after a week-plus in which the White House touted a potentially effective but unproven malaria medication despite the concerns of scientific advisors such as NIAID director Anthony Fauci. And Trump ally Rudy Giuliani has been talking up unproven cell therapy efforts on Twitter.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 82,500+ biopharma pros reading Endpoints daily — and it's free.